Chapter title |
Epigenetic therapy for colorectal cancer.
|
---|---|
Chapter number | 40 |
Book title |
Cancer Epigenetics
|
Published in |
Methods in molecular biology, January 2015
|
DOI | 10.1007/978-1-4939-1804-1_40 |
Pubmed ID | |
Book ISBNs |
978-1-4939-1803-4, 978-1-4939-1804-1
|
Authors |
Vivek Vaish, Tripti Khare, Mukesh Verma, Sharad Khare, Vaish V, Khare T, Verma M, Khare S, Vaish, Vivek, Khare, Tripti, Verma, Mukesh, Khare, Sharad |
Abstract |
Aberrations in epigenome that include alterations in DNA methylation, histone acetylation, and miRNA (microRNA) expression may govern the progression of colorectal cancer (CRC). These epigenetic changes affect every phase of tumor development from initiation to metastasis. Since epigenetic alterations can be reversed by DNA demethylating and histone acetylating agents, current status of the implication of epigenetic therapy in CRC is discussed in this article. Interestingly, DNA methyltransferase inhibitors (DNMTi) and histone deacetylase inhibitors (HDACi) have shown promising results in controlling cancer progression. The information provided here might be useful in developing personalized medicine approaches. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 1 | 100% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 1 | 100% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
United States | 1 | 4% |
Unknown | 22 | 96% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Bachelor | 5 | 22% |
Researcher | 5 | 22% |
Student > Master | 4 | 17% |
Student > Postgraduate | 3 | 13% |
Student > Ph. D. Student | 2 | 9% |
Other | 3 | 13% |
Unknown | 1 | 4% |
Readers by discipline | Count | As % |
---|---|---|
Agricultural and Biological Sciences | 6 | 26% |
Biochemistry, Genetics and Molecular Biology | 5 | 22% |
Medicine and Dentistry | 5 | 22% |
Nursing and Health Professions | 1 | 4% |
Chemical Engineering | 1 | 4% |
Other | 2 | 9% |
Unknown | 3 | 13% |